These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21987746)

  • 21. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
    Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
    Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
    Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.
    Geisbert TW; Lee AC; Robbins M; Geisbert JB; Honko AN; Sood V; Johnson JC; de Jong S; Tavakoli I; Judge A; Hensley LE; Maclachlan I
    Lancet; 2010 May; 375(9729):1896-905. PubMed ID: 20511019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.
    Geisbert TW; Daddario-DiCaprio KM; Williams KJ; Geisbert JB; Leung A; Feldmann F; Hensley LE; Feldmann H; Jones SM
    J Virol; 2008 Jun; 82(11):5664-8. PubMed ID: 18385248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.
    Günther S; Feldmann H; Geisbert TW; Hensley LE; Rollin PE; Nichol ST; Ströher U; Artsob H; Peters CJ; Ksiazek TG; Becker S; ter Meulen J; Olschläger S; Schmidt-Chanasit J; Sudeck H; Burchard GD; Schmiedel S
    J Infect Dis; 2011 Nov; 204 Suppl 3():S785-90. PubMed ID: 21987751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species.
    Bergren NA; Miller MR; Monath TP; Kading RC
    Hum Vaccin Immunother; 2018 Apr; 14(4):994-1002. PubMed ID: 29206076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.
    Kasereka MC; Ericson AD; Conroy AL; Tumba L; Mwesha OD; Hawkes MT
    Vaccine; 2020 Mar; 38(14):3003-3007. PubMed ID: 32093984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability.
    Zhang Y; Wei Y; Li Y; Wang X; Liu Y; Tian D; Jia X; Gong R; Liu W; Yang L
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0008403. PubMed ID: 33711011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters.
    Prescott J; DeBuysscher BL; Brown KS; Feldmann H
    Viruses; 2014 Jan; 6(2):516-23. PubMed ID: 24492621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo.
    Rupani N; Ngole ME; Lee JA; Aluisio AR; Gainey M; Perera SM; Ntamwinja LK; Matafali RM; Muhayangabo RF; Makoyi FN; Laghari R; Levine AC; Kearney AS
    Emerg Infect Dis; 2022 Jun; 28(6):1180-1188. PubMed ID: 35608607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
    Geisbert TW; Daddario-Dicaprio KM; Lewis MG; Geisbert JB; Grolla A; Leung A; Paragas J; Matthias L; Smith MA; Jones SM; Hensley LE; Feldmann H; Jahrling PB
    PLoS Pathog; 2008 Nov; 4(11):e1000225. PubMed ID: 19043556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
    Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
    Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.